Mitchell Krassan

TXMD

CHIEF STRATEGY OFFICER · THERAPEUTICSMD, INC. · CIK 0001532232

FILING MIX · LIFETIME57%/43%

BUYS

SELLS

TOTAL VALUE

$736.3K

COMPANIES

ACTIVE SINCE

Feb 2020

HOLDINGS NOW

151,500

AVG SELL PX

$2.26

Trades · vs SPY

Loading price series…

Performance · forward returns vs SPY

1 backtested trades · 8 horizonsHow are these numbers computed? →

Forward-return performance of every backtestable P/S trade by Mitchell Krassan, measured at 8 horizons from 7 days to 2 years. Deduped per economic event so co-filings count once. Excess return = trade return minus SPY return over the same window.

HORIZON	TRADES	WIN RATE	INSIDER RETURN	SPY RETURN	MEAN EXCESS	MEDIAN EXCESS	T-STAT
7d	1	+0.00%	+8.65%	+3.27%	+5.38%	+5.38%	—
14d	1	+0.00%	+7.32%	+3.90%	+3.42%	+3.42%	—
30d	1	+100.00%	-17.52%	-3.47%	-14.05%	-14.05%	—
60d	1	+100.00%	-59.22%	-22.97%	-36.25%	-36.25%	—
90d	1	+100.00%	-33.92%	-11.99%	-21.93%	-21.93%	—
180d	1	+100.00%	-17.96%	+1.79%	-19.75%	-19.75%	—
1y	1	+100.00%	-22.39%	+19.93%	-42.32%	-42.32%	—
2y	1	+100.00%	-87.36%	+45.67%	-133.04%	-133.04%	—

How to read this: Insider Returnis the average raw return of the filer's trades over the horizon. SPY Return is what SPY did over those same windows — reference only, not a comparison. The headline alpha number is Mean Excess = Insider − SPY; green means the filer beat SPY, red means they trailed it. Win rate is the share of individual trades where the filer beat SPY. T-statvalues above 2 mean the alpha is unlikely to be chance given the sample size. "Pending" counts trades where the horizon hasn't elapsed yet; their stats are not included in the row average.

Holdings over time

TXMD · 151,500 shares · as of Mar 30, 2020

Trading cadence · quarterly flow

BUY ● SELL ●

2020

FLOW · 4 buys / 3 sellsCOVERAGE · 1 quarters

Form 4 filings · all activity

COMPANY	TYPE	SHARES	PRICE	VALUE	HELD AFTER	TRADE DATE	FILED	DETAILS
TXMD THERAPEUTICSMD, INC.	PURCHASEGRANT Stock grant	151,500	—	—	151,500	Mar 30, 2020	Apr 1, 2020 ↗	View →
TXMD THERAPEUTICSMD, INC.	PURCHASEGRANT Stock grant	151,500	—	—	151,500	Mar 30, 2020	Apr 1, 2020 ↗	View →
TXMD THERAPEUTICSMD, INC.	SALE Chief Strategy Officer	105,703	—	—	0	Feb 3, 2020	Feb 5, 2020 ↗	View →
TXMD THERAPEUTICSMD, INC.	SALE Chief Strategy Officer	300,000	$2.26	$676.9K	0	Feb 3, 2020	Feb 5, 2020 ↗	View →
TXMD THERAPEUTICSMD, INC.	PURCHASE Chief Strategy Officer	194,297	$0.20	$39.6K	300,000	Feb 3, 2020	Feb 5, 2020 ↗	View →
TXMD THERAPEUTICSMD, INC.	SALE Chief Strategy Officer	194,297	—	—	489,658	Feb 3, 2020	Feb 5, 2020 ↗	View →
TXMD THERAPEUTICSMD, INC.	PURCHASE Chief Strategy Officer	105,703	$0.19	$19.8K	105,703	Feb 3, 2020	Feb 5, 2020 ↗	View →

Other insiders · TXMD

Loading peer insiders…

About this filer

CIK 0001532232

ROLE

Chief Strategy Officer

PRIMARY

TXMD

COMPANIES

ACTIVE SINCE

Feb 2020

MARKETPEEL · /INSIDER/0001532232DATA · SEC EDGAR · FORM 4 · CONSOLIDATED TAPE

Mitchell Krassan

The morning brief, before the bell.